Cellectar Biosciences Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma Dec 4, 2014
Cellectar Biosciences Names Cameron Szakacs, Ph.D. Vice President of Clinical Development Nov 25, 2014
Cellectar Biosciences Reports Third Quarter 2014 Financial Results and Recent Highlights Nov 11, 2014
Cellectar Biosciences to Host Conference Call on November 11th to Discuss Third Quarter 2014 Results and Provide Quarterly Update on Development Progress Nov 6, 2014
Cellectar Biosciences Announces Publication of Findings Demonstrating Efficacy of Its Phospholipid Ether Analog Platform in Detecting Colorectal Cancer Oct 15, 2014
Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September Sep 5, 2014
Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma Sep 4, 2014
Cellectar Biosciences Reports Second Quarter 2014 Financial Results and Recent Highlights Aug 20, 2014
Cellectar Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option Aug 20, 2014
Cellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress Aug 18, 2014